Genentech Provides Update on Cabilly Patent Reexamination
Wednesday February 21, 9:11 am ET
SOUTH SAN FRANCISCO, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE: DNA - News) announced today that the U.S. Patent and Trademark Office issued a final Office action in its reexamination of the Cabilly, et al. U.S. Patent No. 6,331,415 ('415 patent) and rejected the patentability of the claims of the '415 patent. Genentech plans to respond to the final Office action within the next several months and, if necessary, appeal the decision through all appropriate means of review within the Patent Office and the courts. The U.S. Patent Office has made a copy of the final Office action available to the public on its website.
The '415 patent remains valid and enforceable through the appeals process. The company estimates that the entire appeals process may take approximately one to two years, or longer.
About Genentech
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit gene.com.
Media Contact: Geoff Teeter (650) 225-8171
Caroline Pecquet (650) 467-7078
Investor Contact: Kathee Littrell (650) 225-1034
Sue Morris (650) 225-6523 |
